{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:13:59Z","timestamp":1791670439502,"version":"4.3.4"},"reference-count":83,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":1847,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1093\/annonc\/mdu265","type":"journal-article","created":{"date-parts":[[2014,7,24]],"date-time":"2014-07-24T01:09:18Z","timestamp":1406164158000},"page":"2101-2115","source":"Crossref","is-referenced-by-count":80,"title":["The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck"],"prefix":"10.1016","volume":"25","author":[{"given":"A.","family":"Psyrri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Rampias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.B.","family":"Vermorken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu265_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"suppl 5","key":"10.1093\/annonc\/mdu265_bb0015","doi-asserted-by":"crossref","first-page":"v184","DOI":"10.1093\/annonc\/mdq185","article-title":"Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Gregoire","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0020","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: head and neck cancers. Version 2.2013."},{"key":"10.1093\/annonc\/mdu265_bb0025","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1055-9965.EPI-08-0347","article-title":"Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium","volume":"18","author":"Hashibe","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1093\/annonc\/mdu265_bb0030","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/aje\/kwm193","article-title":"Oral health and risk of squamous cell carcinoma of the head and neck and esophagus: results of two multicentric case-control studies","volume":"166","author":"Guha","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1093\/annonc\/mdu265_bb0035","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jnci\/92.9.709","article-title":"Evidence for a causal association between human papillomavirus and a subset of head and neck cancers","volume":"92","author":"Gillison","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdu265_bb0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3322\/caac.21167","article-title":"The role of human papillomavirus in nongenital cancers","volume":"63","author":"Zandberg","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdu265_bb0045","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0050","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hed.22015","article-title":"Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region","volume":"35","author":"Mehanna","year":"2013","journal-title":"Head Neck"},{"key":"10.1093\/annonc\/mdu265_bb0055","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1016\/j.vaccine.2010.02.098","article-title":"Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets","volume":"28","author":"Hong","year":"2010","journal-title":"Vaccine"},{"key":"10.1093\/annonc\/mdu265_bb0060","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1055-9965.EPI-04-0551","article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review","volume":"14","author":"Kreimer","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1093\/annonc\/mdu265_bb0065","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1056\/NEJMoa065497","article-title":"Case-control study of human papillomavirus and oropharyngeal cancer","volume":"356","author":"D'Souza","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu265_bb0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev.pathol.4.110807.092158","article-title":"Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment","volume":"4","author":"Pai","year":"2009","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"10.1093\/annonc\/mdu265_bb0075","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.oraloncology.2013.07.011","article-title":"Molecular mechanisms of HPV induced carcinogenesis in head and neck","volume":"50","author":"Rampias","year":"2014","journal-title":"Oral Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0080","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0092-8674(93)90384-3","article-title":"The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53","volume":"75","author":"Scheffner","year":"1993","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdu265_bb0085","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/jnci\/djp017","article-title":"E6 and E7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells","volume":"101","author":"Rampias","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdu265_bb0090","first-page":"4620","article-title":"E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway","volume":"56","author":"Boyer","year":"1996","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu265_bb0095","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/355176a0","article-title":"Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F","volume":"355","author":"Cao","year":"1992","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdu265_bb0100","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1126\/science.2537532","article-title":"The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product","volume":"243","author":"Dyson","year":"1989","journal-title":"Science"},{"key":"10.1093\/annonc\/mdu265_bb0105","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1200\/JCO.2004.00.3335","article-title":"Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis","volume":"24","author":"Weinberger","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/path.2227","article-title":"Gene expression profiles in HPV-infected head and neck cancer","volume":"213","author":"Schlecht","year":"2007","journal-title":"J Pathol"},{"key":"10.1093\/annonc\/mdu265_bb0115","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1093\/annonc\/mdt013","article-title":"Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype","volume":"24","author":"Rampias","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0120","series-title":"AACR Annual Meeting, Washington, DC, 7 April","article-title":"Comprehensive genomic characterization of squamous cell carcinoma of the head and neck in the Cancer Genome Atlas","author":"Hayes","year":"2013"},{"key":"10.1093\/annonc\/mdu265_bb0125","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.oraloncology.2009.11.004","article-title":"Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer","volume":"46","author":"D'Souza","year":"2010","journal-title":"Oral Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/jnci\/djn025","article-title":"Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers","volume":"100","author":"Gillison","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdu265_bb0135","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1002\/ijc.23458","article-title":"Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas","volume":"122","author":"Hafkamp","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdu265_bb0140","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2012.44.0164","article-title":"Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis","volume":"31","author":"O'Sullivan","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0145","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2010.29.2904","article-title":"Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial","volume":"28","author":"Rischin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0150","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1200\/JCO.2009.27.4449","article-title":"Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group","volume":"28","author":"Rischin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0155","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu265_bb0160","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.6001","article-title":"Impact of p16 status on the results of the phase III cetuximab (cet)\/radiotherapy (RT)","volume":"32","author":"Rosenthal","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0165","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.5510","article-title":"Analysis of the effect of p16 and tobacco pack-years (p-y) on overall (OS) and progression-free survival (PFS) for patients with oropharynx cancer (OPC) in Radiation Therapy Oncology Group (RTOG) protocol 9003","volume":"28","author":"Gillison","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0360-3016(00)00663-5","article-title":"A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003","volume":"48","author":"Fu","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdu265_bb0175","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdr006","article-title":"Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial","volume":"22","author":"Posner","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0180","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu265_bb0185","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.2008.20.2853","article-title":"Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck","volume":"27","author":"Lassen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0190","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.radonc.2009.10.008","article-title":"HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer","volume":"94","author":"Lassen","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0167-8140(97)00220-X","article-title":"A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5\u201385","volume":"46","author":"Overgaard","year":"1998","journal-title":"Radiother Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0200","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.5500","article-title":"A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC)","volume":"29","author":"Ang","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0205","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djn011","article-title":"Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial","volume":"100","author":"Fakhry","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdu265_bb0210","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.5515","article-title":"Expression of p16, ERCC1, and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib: a phase II randomized trial","volume":"30","author":"Austin","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0215","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.5502","article-title":"A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN)","volume":"30","author":"Giralt","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0220","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mds402","article-title":"Phase 2, randomized trial (CONCERT-2) of panitumumab (pmab) plus radiotherapy (PRT) compared with chemoradiotherapy (CRT) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN)","volume":"23","author":"Giralt","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0225","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.5537","article-title":"Tumor molecular correlates of unresectable, locally advanced head and neck squamous cell carcinoma (SCCHN) response to concurrent radiation (RT), cisplatin (DDP), and cetuximab (C225) in a phase II trial (ECOG 3303)","volume":"28","author":"Egloff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0230","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.ejca.2012.11.023","article-title":"Randomised phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease","volume":"49","author":"Harrington","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu265_bb0235","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00405-010-1396-7","article-title":"Impact of HPV infection on the clinical outcome of p-CAIR trial in head and neck cancer","volume":"268","author":"Snietura","year":"2011","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1093\/annonc\/mdu265_bb0240","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cncr.26364","article-title":"Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer","volume":"118","author":"Gilbert","year":"2012","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu265_bb0245","first-page":"1467","article-title":"Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial","volume":"29","author":"Jo","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdu265_bb0250","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.2009.23.0425","article-title":"Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial","volume":"28","author":"Kies","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0255","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2010.30.6423","article-title":"Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer","volume":"28","author":"Argiris","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0260","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.6005","article-title":"Final analysis: a randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN)","volume":"32","author":"Harrington","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdu265_bb0265","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ijrobp.2013.11.023","article-title":"Human papillomavirus (HPV) and overall survival (OS) after progression of oropharyngeal squamous cell carcinoma (OPSCC)","volume":"88","author":"Fakhry","year":"2014","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdu265_bb0270","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu265_bb0275","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0280","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.oraloncology.2012.07.015","article-title":"Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer","volume":"49","author":"Huang","year":"2013","journal-title":"Oral Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdu265_bb0285","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1002\/ijc.22980","article-title":"A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen","volume":"121","author":"Smeets","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdu265_bb0290","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu265_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/S0923-7534(20)33592-4","article-title":"Safety and efficacy of cisplatin plus 5-FU and cetuximab in HPV-positive and HPV-negative recurrent and\/or metastatic squamous cell carcinoma of the head and neck (R\/M SCCHN): analysis of the phase III EXTREME trial","volume":"23","author":"Psyrri","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0300","article-title":"EXTREME (PF+\/-cetuximab) and SPECTRUM (PF+\/-panitumumab): HPV status and outcome","volume":"107","author":"Vermorken","year":"2013","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdu265_bb0305","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/annonc\/mdt574","article-title":"Impact of tumor HPV status on outcome in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial","volume":"25","author":"Vermorken","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0310","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1470-2045(13)70181-5","article-title":"Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial","volume":"14","author":"Vermorken","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0315","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.6006","article-title":"Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R\/M SCCHN)","volume":"31","author":"Mehra","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0320","series-title":"Multidisciplinary Head and Neck Cancer Symposium","article-title":"A randomized, open-label, phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck\u2014final data","author":"Seiwert","year":"2012"},{"key":"10.1093\/annonc\/mdu265_bb0325","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.6029","article-title":"PARTNER: a randomized phase II study of docetaxel\/cisplatin (doc\/cis) chemotherapy with or without panitumumab (pmab) as first-line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R\/M SCCHN)","volume":"31","author":"Wirth","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0330","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.6047","article-title":"Cetuximab with or without sorafenib in recurrent\/metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN)","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0335","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.6041","article-title":"Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent\/metastatic SCCHN from a phase II trial","volume":"31","author":"Audet","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0340","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.6007","article-title":"p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC)","volume":"31","author":"Chung","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0345","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.6008","article-title":"Multimodality determination of HPV status in head and neck cancers (HNC) and development of an HPV signature","volume":"31","author":"Zuo","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0350","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00405-013-2603-0","article-title":"New treatment strategies for HPV-positive head and neck cancer","volume":"271","author":"Kofler","year":"2014","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1093\/annonc\/mdu265_bb0355","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2407-13-26","article-title":"Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer","volume":"13","author":"Pajares","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdu265_bb0360","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1200\/JCO.2012.46.7746","article-title":"Controversies in treatment deintensification of human papillomavirus-associated oropharyngeal carcinomas: should we, how should we, and for whom?","volume":"31","author":"Quon","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0365","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1200\/JCO.2011.38.4099","article-title":"Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer","volume":"30","author":"Gillison","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0370","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1093\/annonc\/mdt319","article-title":"Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials","volume":"24","author":"Rietbergen","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0375","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.6005","article-title":"E 1308: a phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC)","volume":"31","author":"Marur","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0380","unstructured":"ClinicalTrials.gov. Radiation therapy with cisplatin or cetuximab in treating patients with oropharyngeal cancer. 2013; http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01302834 (10 July 2014, date last accessed)"},{"key":"10.1093\/annonc\/mdu265_bb0385","unstructured":"Radiation Therapy Oncology Group 2013. RTOG 1016 protocol information http:\/\/www.rtog.org\/ClinicalTrials\/ProtocolTable\/StudyDetails.aspx?study=1016 (13 August 2014, date last accessed)"},{"key":"10.1093\/annonc\/mdu265_bb0390","unstructured":"EU Clinical Trials Register 2013. De-ESCALaTE HPV: determination of epidermal growth factor receptor-inhibitor (cetuximab) versus standard chemotherapy (cisplatin) early and late toxicity events in human papillomavirus-positive oropharyngeal squamous cell carcinoma https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005165-21\/GB (13 August 2014, date last accessed)"},{"key":"10.1093\/annonc\/mdu265_bb0395","unstructured":"Current Controlled Trials. De-ESCALaTE HPV: determination of epidermal growth factor receptor-inhibitor (cetuximab) versus standard chemotherapy (cisplatin) early and late toxicity events in human papillomavirus-positive oropharyngeal squamous cell carcinoma. 2013; http:\/\/www.controlled-trials.com\/ISRCTN33522080 (10 July 2014, date last accessed)"},{"key":"10.1093\/annonc\/mdu265_bb0400","unstructured":"ClincalTrials.gov. The Quarterback trial. 2013; http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01706939 (10 July 2014, date last accessed)"},{"key":"10.1093\/annonc\/mdu265_bb0405","unstructured":"Clinicaltrials.gov. Post operative adjuvant therapy de-intensification trial for human papillomavirus-related, p16+ oropharynx cancer (ADEPT). 2013; http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01687413 (10 July 2014, date last accessed)."},{"key":"10.1093\/annonc\/mdu265_bb0410","unstructured":"ClincalTrials.gov. Transoral surgery followed by low-dose or standard-dose radiation therapy with or without chemotherapy in treating patients with HPV positive stage III-IVA oropharyngeal cancer. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01898494?term=E3311&rank=1 (10 July 2014, date last accessed)"},{"issue":"3","key":"10.1093\/annonc\/mdu265_bb0415","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/annonc\/mdu004","article-title":"Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile; a tertiary cancer centre series analysis","volume":"25","author":"Bossi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu265_bb0420","unstructured":"EORTC. Transgene collaborates with EORTC on phase 2b trial with TG4001 in head & neck cancer. 2013; http:\/\/www.eortc.org\/news\/transgene-collaborates-eortc-phase-2b-trial-tg4001-head-neck-cancer (10 July 2014, date last accessed)"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341936764X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341936764X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/11\/2101\/324376\/mdu265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:32:28Z","timestamp":1624505548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341936764X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":83,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S092375341936764X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu265","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}